Anvisa: On Thursday (16), the National Health Surveillance Agency (Anvisa) approved the immunization of children with the vaccine developed by Pfizer in partnership with BioNTech. Tests conducted by the companies showed that the immunizing agent is highly effective in little ones.
Authorization for the use of the SARS-CoV-2 coronavirus vaccine has also been carried out in other countries, such as the United States, Colombia, Peru, Honduras, Uruguay, El Savador, Ecuador, the Dominican Republic and also in the European Union. There is still no forecast when immunization in children should start in Brazil.
Different vaccine for children
Despite using a similar formula, the vaccine for children is different from the version for adults. For example, the dose for children 11 years and under is 10 micrograms, volume of 0.2 ml, mRNA concentration of 0.1 mg and 1.3 ml of diluent — in comparison, immunization for adults and over 12 years has 30 microgram dose, 0.3 ml volume, 0.5 mg mRNA concentration and 1.8 ml diluent.
“The reduction in dosage for the 5 to 11 year age group was supported by Phase 1 and 2 studies, which showed that this dosage (10 micrograms) was enough to generate high antibody titers with a very favorable safety profile for the population pediatrics,” Pfizer said in a statement.